Global Obsessive-Compulsive Disorder (OCD) Drugs Market is expected to grow with a CAGR of 9.7% in the forecast period of 2021 to 2028. The years considered for the study areas mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-obsessive-compulsive-disorder-ocd-drug-market

Global Obsessive-Compulsive Disorder (OCD) drugs market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenarios.   

The major players dealing in the global obsessive-compulsive disorder (OCD) drugs market are introducing a strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement, business expansion, award, and recognition into the market. This helped companies to maximize the sales with enhanced product portfolio.

For instance:

• In August 2020, Sun Pharmaceutical Industries Limited announced that it had launched FluGuard (Favipiravir 200 mg) at an economical price of Rs. 35 per tablet for the treatment of mild to moderate cases of COVID-19 in India. Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate COVID-19 disease. The company is launching FluGuard at an economical price to make the drug accessible to more and more patients, thereby reducing their financial burden. This has supported India’s pandemic response. 

Sun Pharmaceutical Industries Ltd. is the dominating player in global obsessive-compulsive disorder (OCD) drugs market. The other key players existing in the market are H. LUNDBECK A/S, Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.), Abbott, Eli Lilly and Company, Viatria Inc., , GlaxoSmithKline plc., Pfizer Inc., Mallinckrodt, Sebela Pharmaceuticals, Zydus Pharmaceuticals, Inc. (a subsidiary of Zydus Cadila), Lupin Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC., Dr. Reddy’s Laboratories Ltd., , Wockhardt, Alvogen, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma USA (a subsidiary of Aurobindo Pharma), Par Pharmaceutical, Apotex Inc., Lannett, among others.

Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries Ltd. headquarter is in Maharashtra, India, founded in 1983. The company mainly works in the area of pharmaceutical products. It manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients. The company operates its business through several business segments that are US Business, Indian Branded Generics Business, Emerging Markets, API Business, Global Consumer Healthcare Business, and Rest of the World, in which Indian Branded Generics Business is market focused product. The company has wide product categories such as Specialty Medications, Generic Medications, Over-the-Counter Medications, Active Pharmaceutical Ingredients, and Anti Retro Viral Medications, in which Generic Medications is the market focused category. The company is attaining lucrative growth through several strategic initiatives.

For instance,

• In June 2021, Sun Pharmaceutical Industries Ltd. announced that one of its wholly owned subsidiaries has entered into a license agreement with Ferring Pharmaceuticals Pvt. Ltd. (Ferring), a subsidiary of Switzerland-based biopharmaceuticals MNC Ferring Pharmaceuticals, to commercialize a Room Temperature Stable (RTS) formulation of the obstetric drug, CARITEC® (Carbetocin RTS) in India. As per agreement terms, Sun Pharma is granted rights for co-marketing the medicine in India in the private market under the brand name CARITEC®. Ferring has developed the drug and received approval from the Drugs Controller General of India (DCGI) for introducing the drug in India.

The company has wide presence across North America, South America, Europe, Asia-Pacific, Oceania, and CIS. The company also has various subsidiary companies such as Sun Pharmaceutical (Bangladesh) Limited, Sun Pharma Laboratories Limited (India), Sun Pharma Holdings (Mauritius), Sun Pharmaceutical Industries Inc. (United States of America), Sun Pharmaceutical Industries (Australia) Pty Limited (Australia) among others.  as Thermo Trace Limited (Australia), Thermo Electron A/S (France), Jouan Limited (England), Jouan Nordic AS (Denmark), JSC Thermo Electron (Russia), among others.  

H. LUNDBECK A/S

H. LUNDBECK A/S founded in 1915. The company’s headquarter is in Copenhagen, Denmark. The company is focused on treating millions of people suffering from brain disease with the specialized products. The company has wide product categories such as Neurological Disorders, Psychiatric Disorders, and Other Disease, in which Psychiatric Disorders is the market focused product. The company is attaining lucrative growth through several strategic initiatives.  

• In April 2021, H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announce the decision to continue the recruitment of patients in the phase III clinical trial of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type (NCT03548584). The continuation of the study enables Lundbeck and Otsuka to further explore the efficacy of brexpiprazole to address the high medical need in patients suffering from agitation in Alzheimer’s type dementia. Completion of the trial is expected in the first half of 2022. 

The company has wide presence across Africa, Americas, Asia-Pacific, and Europe. The company also has various subsidiary companies such as Lundbeck S.A. (Belgium), CNS Pharma Pty Ltd (Australia), Lundbeck Austria GmbH (Austria), Lundbeck Export A/S (Denmark), Prexton Therapeutics S.A. (Switzerland) among others.

Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.)

Teva Pharmaceuticals USA, Inc., headquartered in New Jersey, U.S., founded in 1985. The company assist patients to live longer and healthier life with increasing access to quality health to millions of people around the world. The company has various product categories that are Generic Medicines, Specialty Medicines, and Biopharmaceuticals, in which Generic Medicines is the market focused product. The company is attaining lucrative growth through several strategic initiatives.

For instance,

• In April 2021, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced its launch of the first available 10 mg, 20 mg, 25 mg, 30 mg, 35 mg, and 40 mg strength generic version of Absorica®1 (isotretinoin) capsules for the treatment of severe recalcitrant nodular acne in non-pregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5 mm or greater.

The company has presence across North America, Europe, Asia-Pacific, Middle East, Africa, and Latin America. The company also has various subsidiary companies such as Teva Canada (Canada), Ratiopharm (Germany), Mepha Schweiz AG (Switzerland), Merckle GmbH (Germany), PLIVA HRVATSKA d.o.o (Croatia), among others.